Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 531 to 540 of 1447 total matches.
Spritam - A New Formulation of Levetiracetam for Epilepsy
The Medical Letter on Drugs and Therapeutics • Jun 20, 2016 (Issue 1497)
is $130.00.
79
The Medical Letter ® Vol. 58 (1497) June 20, 2016
1. Drugs for epilepsy. Treat Guidel Med ...
The FDA has approved a rapidly disintegrating tablet
formulation of the antiepileptic drug levetiracetam
(Spritam – Aprecia) for adjunctive treatment of partialonset,
myoclonic, and primary generalized tonicclonic
seizures. Oral and intravenous formulations
of levetiracetam (Keppra, and generics) have been
available for years. Although approved by the FDA only
as adjunctive therapy, levetiracetam is commonly used
as monotherapy for partial-onset and generalized
seizures and may also be effective in treating absence
seizures and seizures of Lennox-Gastaut syndrome.
A New Abuse-Deterrent Opioid - Xtampza ER
The Medical Letter on Drugs and Therapeutics • Jun 20, 2016 (Issue 1497)
.
For further information call: 800-211-2769
78
The Medical Letter ® Vol. 58 (1497) June 20, 2016 ...
The FDA has approved Xtampza ER (Collegium),
a new extended-release, abuse-deterrent capsule
formulation of oxycodone, for management of pain
severe enough to require daily, around-the-clock,
long-term opioid treatment and for which alternative
treatment options are inadequate.
Two New Amphetamines for ADHD
The Medical Letter on Drugs and Therapeutics • Jun 20, 2016 (Issue 1497)
.
81
The Medical Letter ® Vol. 58 (1497) June 20, 2016
Dyanavel XR extended-release oral suspension ...
Two new extended-release amphetamine products
have been approved by the FDA for once-daily
treatment of attention-deficit/hyperactivity disorder
(ADHD) in patients ≥6 years old: Adzenys XR-ODT
(Neos Therapeutics), an orally distintegrating tablet,
and Dyanavel XR (Tris Pharma), an oral suspension.
Reslizumab (Cinqair) for Severe Eosinophilic Asthma
The Medical Letter on Drugs and Therapeutics • Jun 20, 2016 (Issue 1497)
.5
82
The Medical Letter ® Vol. 58 (1497) June 20, 2016
The fourth study included patients 18-65 ...
The FDA has approved reslizumab (Cinqair – Teva), a
humanized interleukin-5 (IL-5) antagonist monoclonal
antibody, for add-on maintenance treatment of severe
asthma in adults who have an eosinophilic phenotype.
It is the second IL-5 antagonist to be approved in the
US; mepolizumab (Nucala) was approved for the same
indication in 2015.
Pimavanserin (Nuplazid) for Parkinson's Disease Psychosis
The Medical Letter on Drugs and Therapeutics • Jun 06, 2016 (Issue 1496)
,
the dosage of pimavanserin should be reduced to
75
The Medical Letter ® Vol. 58 (1496) June 6, 2016
17 mg ...
The FDA has approved the atypical antipsychotic
pimavanserin (Nuplazid – Acadia) for treatment
of hallucinations and delusions associated with
Parkinson's disease. It is the first drug to be approved
in the US for this indication.
Alternatives to Fluoroquinolones
The Medical Letter on Drugs and Therapeutics • Jun 06, 2016 (Issue 1496)
The Medical Letter ® Vol. 58 (1496) June 6, 2016
such as amoxicillin/clavulanate, cefdinir, cefpodoxime ...
The FDA has announced that it is requiring changes in
the labeling of systemic fluoroquinolones to warn that
the risk of serious adverse effects, including tendinitis,
peripheral neuropathy and CNS effects, generally outweighs
their benefit for the treatment of acute sinusitis,
acute exacerbations of chronic bronchitis, and uncomplicated
urinary tract infections. For these infections, the
new labels will recommend reserving fluoroquinolones
for patients with no other treatment options.
Antimicrobial Prophylaxis for Surgery
The Medical Letter on Drugs and Therapeutics • May 23, 2016 (Issue 1495)
of this material is strictly prohibited.
For further information call: 800-211-2769
64
The Medical Letter ® Vol ...
Antimicrobial prophylaxis can decrease the
incidence of postoperative surgical site infection
after some procedures. Since the last Medical Letter
article on this subject, consensus guidelines have
been published. Recommendations for prophylaxis
in specific surgical procedures are listed in Table 1.
Three New Drugs for Multiple Myeloma (online only)
The Medical Letter on Drugs and Therapeutics • May 23, 2016 (Issue 1495)
of a randomized, double-blind
trial comparing ixazomib plus lenalidomide and
e71
The Medical Letter ® Vol. 58 ...
The FDA recently approved ixazomib (Ninlaro –
Takeda), daratumumab (Darzalex – Janssen Biotech),
and elotuzumab (Empliciti – BMS) for treatment of
relapsed and/or refractory multiple myeloma.
QuilliChew ER - Extended-Release Chewable Methylphenidate Tablets
The Medical Letter on Drugs and Therapeutics • May 23, 2016 (Issue 1495)
evaluated using the SKAMP-Combined score,
69
The Medical Letter ® Vol. 58 (1495) May 23, 2016
CONCLUSION ...
The FDA has approved a once-daily, extended-release
chewable tablet formulation of methylphenidate
(QuilliChew ER – Pfizer) for treatment of attention-deficit/hyperactivity disorder (ADHD). It is the first
long-acting chewable formulation of the drug to be
marketed in the US. Immediate-release chewable
methylphenidate tablets (Methylin, and generics) have
been available since 2003.
Ciprofloxacin (Otiprio) for Tympanostomy Tube Insertion
The Medical Letter on Drugs and Therapeutics • May 23, 2016 (Issue 1495)
Letter ® Vol. 58 (1495) May 23, 2016
children with bilateral otitis media with effusion, can
reduce ...
The FDA has approved ciprofloxacin 6% otic
suspension (Otiprio – Otonomy) for single-dose
prophylaxis in children with bilateral otitis media
with effusion who are undergoing tympanostomy
tube placement. It is the first drug to be approved
for this indication in the US. Otic formulations
of the fluoroquinolone antibiotics ofloxacin
(Floxin Otic, and generics) and ciprofloxacin (plus
dexamethasone; Ciprodex) have been available for
years for treatment of acute otitis media in children
with tympanostomy tubes; an otic suspension
containing ciprofloxacin and fluocinolone...